Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 11
2004 6
2005 10
2006 16
2007 26
2008 11
2009 18
2010 25
2011 23
2012 25
2013 18
2014 26
2015 40
2016 29
2017 32
2018 38
2019 35
2020 56
2021 64
2022 57
2023 56
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

562 results

Results by year

Filters applied: . Clear all
Page 1
Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs.
Perrino M, Voulaz E, Balin S, Cazzato G, Fontana E, Franzese S, Defendi M, De Vincenzo F, Cordua N, Tamma R, Borea F, Aliprandi M, Airoldi M, Cecchi LG, Fazio R, Alloisio M, Marulli G, Santoro A, Di Tommaso L, Ingravallo G, Russo L, Da Rin G, Villa A, Della Bella S, Zucali PA, Mavilio D. Perrino M, et al. Among authors: santoro a. Front Immunol. 2024 Apr 2;15:1288045. doi: 10.3389/fimmu.2024.1288045. eCollection 2024. Front Immunol. 2024. PMID: 38629065 Free PMC article. Review.
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer.
Saltalamacchia G, Torrisi R, De Sanctis R, Masci G, Miggiano C, Gaudio M, Benvenuti C, Jacobs F, Gerosa R, Santoro A, Zambelli A. Saltalamacchia G, et al. Among authors: santoro a. Biomedicines. 2024 Feb 23;12(3):500. doi: 10.3390/biomedicines12030500. Biomedicines. 2024. PMID: 38540113 Free PMC article. Review.
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Zinzani PL, Salles GA, Moskowitz AJ, Santoro A, Mehta A, Barr PM, Mehta-Shah N, Collins GP, Ansell SM, Brody JD, Domingo-Domenech E, Johnson NA, Cunningham D, Ferrari S, Lisano JM, Krajewski J, Wen R, Akyol A, Crowe R, Savage KJ. Zinzani PL, et al. Among authors: santoro a. Blood Adv. 2024 Mar 26:bloodadvances.2023011030. doi: 10.1182/bloodadvances.2023011030. Online ahead of print. Blood Adv. 2024. PMID: 38531062 No abstract available.
Brentuximab Vedotin and Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma: a Propensity Score Matched Analysis.
Driessen J, de Wit F, Herrera AF, Zinzani PL, LaCasce AS, Cole PD, Moskowitz CH, García-Sanz R, Fuchs M, Mueller H, Borchmann P, Santoro A, Schöder H, Zijlstra JM, Hutten BA, Moskowitz AJ, Kersten MJ. Driessen J, et al. Among authors: santoro a. Blood Adv. 2024 Mar 19:bloodadvances.2023012145. doi: 10.1182/bloodadvances.2023012145. Online ahead of print. Blood Adv. 2024. PMID: 38502227
Lynch Syndrome: From Multidisciplinary Management to Precision Prevention.
Dal Buono A, Puccini A, Franchellucci G, Airoldi M, Bartolini M, Bianchi P, Santoro A, Repici A, Hassan C. Dal Buono A, et al. Among authors: santoro a. Cancers (Basel). 2024 Feb 20;16(5):849. doi: 10.3390/cancers16050849. Cancers (Basel). 2024. PMID: 38473212 Free PMC article. Review.
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.
Gerosa R, De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Saltalamacchia G, Torrisi R, Masci G, Miggiano C, Agustoni F, Pedrazzoli P, Santoro A, Zambelli A. Gerosa R, et al. Among authors: santoro a. Crit Rev Oncol Hematol. 2024 Apr;196:104324. doi: 10.1016/j.critrevonc.2024.104324. Epub 2024 Mar 8. Crit Rev Oncol Hematol. 2024. PMID: 38462150 Free article. Review.
562 results